Successful clinical-trial results recently made Scholar Rock one of the stock market's top performers. Shares of Scholar Rock (SRRK -13.97%) shot 364% higher on Monday, Oct. 7, 2024. The market was reacting to surprisingly positive news regarding the clinical-stage drugmaker's lead candidate, apitegromab. If you're like the vast majority of individual investors, you've never heard of Scholar Rock, apitegromab, or the muscle-wasting disease it could treat. Here's a quick look at the results that excited savv ...